Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 59

Using creatine to help treat depression in methamphetamine users

Official title: An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users

Run by Montana State University · NCT02568878 · Data updated 2026-11-12

This study is testing if creatine can help reduce depression and anxiety in people who are dependent on methamphetamine.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 59 Years
SexAll
Enrollment29 (estimated)
SponsorMontana State University
Academic / other
Locations1 site (Missoula, Montana)
StatusRecruiting
StartedNovember 2015
Main results expectedOctober 2016
Study endsMay 2017
Registry record updatedDecember 11, 2015
Trial IDNCT02568878 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with a primary diagnosis of methamphetamine dependence, major depressive disorder, and an anxiety disorder.

Probably not a fit

Patients with primary substance-related diagnoses other than methamphetamine dependence or those with significant medical or neurological illnesses may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of creatine monohydrate on depression and anxiety in male and female individuals who are dependent on methamphetamine. It aims to determine whether creatine can alleviate depressive symptoms and reduce methamphetamine use while also assessing its safety in this population. Participants must have a current diagnosis of methamphetamine dependence, major depressive disorder, and an anxiety disorder, with specific severity scores on standardized scales. The study will monitor the participants' responses to creatine over a defined treatment period.

Why it matters

Potential benefit: If successful, this study could provide a novel treatment option for individuals struggling with depression and methamphetamine dependence.

How similar studies have gone: While the use of creatine for depression is an emerging area of interest, this specific application in methamphetamine users is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse
* Current diagnosis of major depressive disorder (primary or substance-induced)
* Current diagnosis of an anxiety disorder (primary or substance-induced)
* Current Hamilton Depression Rating scale score \> or = to 16
* Current Hamilton Anxiety Scale score \> = to 18
* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation

Exclusion Criteria:

* Persons unable to provide adequate informed consent
* Persons who are at clinically significant suicidal or homicidal risk
* Primary substance-related diagnosis other than methamphetamine dependence or abuse
* Positive pregnancy test (females only)
* History of renal disease
* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing
* History of hypersensitivity reaction to creatine

Where it's running

  • Montana State University College of Nursing (Missoula campus)
    Missoula, Montana, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.